All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

Annals of Hematology

Volumn 94, Issue 8, 2015, Pages 1347-1356

  Sanz, Miguel A ^a,b   Montesinos, Pau ^a,b   Kim, Haesook T ^c   Ruiz Argüelles, Guillermo J ^d   Undurraga, María S ^e   Uriarte, María R ^f   Martínez, Lem ^f   Jacomo, Rafael H ^g   Gutiérrez Aguirre, Homero ^h   Melo, Raul A M ⁱ   Bittencourt, Rosane ^j   Pasquini, Ricardo ^k   Pagnano, Katia ^l   Fagundes, Evandro M ^m   Vellenga, Edo ⁿ   Holowiecka, Alexandra ^o   González Huerta, Ana J ^p   Fernández, Pascual ^q   De La Serna, Javier ^r   Brunet, Salut ^s   De Lisa, Elena ^t   González Campos, José ^u   Ribera, José M ^v   Krsnik, Isabel ^w   Ganser, Arnold ^x   Berliner, Nancy ^y   Ribeiro, Raul C ^z   Lo Coco, Francesco ^aa,ab   Löwenberg, Bob ^ac   Rego, Eduardo M ^g   more..

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Clinica Ruiz   (Mexico)

^e HOSPITAL DEL SALVADOR   (Chile)

^f Asociacion Espanola Primera de Socorros Mutuos   (Uruguay)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

ⁱ Fundacao Hemope   (Brazil)

^j FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^k FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^l UNIVERSITY OF CAMPINAS   (Brazil)

^m FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o MEDICAL UNIVERSITY OF SILESIA   (Poland)

^p HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^q HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s Hospital Sant Pau   (Spain)

^t HOSPITAL MACIEL   (Uruguay)

^u HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^v HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^w HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^x HANNOVER MEDICAL SCHOOL   (Germany)

^y BRIGHAM AND WOMEN S HOSPITAL   (United States)

^z ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^aa UNIVERSITY OF ROME TOR VERGATA   (Italy)

^ab IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^ac ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Acute promyelocytic leukaemia; All trans retinoic acid; Anthracyclines; Cytarabine; Matched pair analysis; Prognostic factors; Risk adapted therapy

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; LEUKEMIA, PROMYELOCYTIC, ACUTE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 84941038904     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2393-0     Document Type: Article

References (19)

1. Rego EM, Kim HT, Ruiz-Argüelles GJ et al (2013) Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 121:1935-1943. doi:10.1182/blood-2012-08-449918
2. Jácomo RH, Melo RAM, Souto FR et al (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92:1431-1432. doi:10.3324/haematol.10874
3. Sanz MA, Montesinos P, Rayón C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137-5146. doi:10.1182/blood-2010-01-266007
4. Adès L, Sanz MA, Chevret S et al (2008) Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 111:1078-1084. doi:10.1182/blood-2007-07-099978
5. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
6. Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649. doi:10.1200/JCO.2003.04.036
7. Sanz MA, Lo-Coco F, Martín G et al (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253
8. Montesinos P, Bergua JM, Vellenga E et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775-783. doi:10.1182/blood-2008-07-168617
9. Diamond A, Sekhon JS (2013) Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies. Rev Econ Stat 95:932-945. doi:10.1162/REST_a_00318
10. Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154. doi:10.1214/aos/1176350951
11. Pepe MS, Mori M (1993) Kaplan—Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737-751. doi:10.1002/sim.4780120803
12. Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111-121. doi:10.1056/NEJMoa1300874
13. Powell BL, Moser B, Stock W et al (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116:3751-3757. doi:10.1182/blood-2010-02-269621
14. Iland HJ, Bradstock K, Supple SG et al (2012) All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120:1570-1580. doi:10.1182/blood-2012-02-410746,quiz1752
15. Gore SD, Gojo I, Sekeres MA et al (2010) Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28:1047-1053. doi:10.1200/JCO.2009.25.5158
16. Ravandi F, Estey E, Jones D et al (2009) Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504-510. doi:10.1200/JCO.2008.18.6130
17. Hu J, Liu Y-F, Wu C-F et al (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 106:3342-3347. doi:10.1073/pnas.0813280106
18. Ghavamzadeh A, Alimoghaddam K, Rostami S et al (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753-2757. doi:10.1200/JCO.2010.32.2107
19. Mathews V, George B, Chendamarai E et al (2010) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 28:3866-3871. doi:10.1200/JCO.2010.28.5031